Published in 2017 – Ann Oncol (2017) 28 (suppl 4): iv62–iv71
Authors: M. Dreyling, E. Campo, O. Hermine, M. Jerkeman, S. Le Gouill, S. Rule, O. Shpilberg, J. Walewski and M. Ladetto
Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations for first-line and relapsed disease including the leukaemic non-nodal subtype. Also covered is a summary of recent phase II/III trials investigating dose-intensified first-line therapy in mantle cell lymphoma and a list of published clinical studies investigating molecular targeted approaches for patients in the relapsed stage.